All News

The discontinuation of opioid therapy may address the rising death toll caused by drug overdoses while maintaining or potentially improving chronic, non-cancer pain in patients, according to a recent study.

With this new indication, enzalutamide is the first and only FDA-approved oral medication for both non-metastatic and metastatic CRPC.

With Amazons purchase of PillPack, it leaves me wondering what other companies they may be considering in the pharmacy space.

Student pharmacists at 2 universities in vastly different communities will learn how the other half practices pharmacy during a new program that will send each group across the country.

Some companies are recalling all lots of non-expired products that contain the ingredient valsartan supplied by a third-party.

Pharmacists will provide first aid and over-the-counter treatments along the RAGBRAI route, which stretches more than 400 miles across Iowa.

Cognitive impairment is present in up to 70% of patients with multiple sclerosis, but can be difficult to completely evaluate in routine clinical practice.

Top news of the week from The American Journal of Pharmacy Benefits.

Top news of the week from Specialty Pharmacy Times.

SensorRx is utilizing patient-generated health data that links to the physician in order to improve outcomes for the patient population.

Significant progress has been made in gene therapy research and development over the years, with promise to treat and cure some of the most complex diseases.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

The FDA has issued disease-specific draft guidances for the development of gene therapies for certain conditions.

Mobile health interventions have the potential to help people living with HIV improve engagement in care, promote medication adherence, and in turn, improve patient outcomes.

A personalized medicine knowledge gap currently exists between many healthcare providers in the United States, and around the globe.

Nivolumab (Opdivo) plus ipilimumab (Yervoy) approved for patients with microsatellite instability high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Research to explore whether intermittent fasting can improve symptoms in patients with relapsing-remitting multiple sclerosis.

Point-of-care testing can help patients determine whether or not they need to see a prescriber for an antibiotic or for other types of treatment, and it can address the growing primary care provider shortage.

Olaparib (Lynparza, Merck and AstraZeneca) demonstrated significant improvement in progression-free survival in the first-line maintenance setting for women with advanced BRCA-mutated ovarian cancer.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

An experimental HIV-1 vaccine regimen was well-tolerated and produced immune responses against HIV in humans and rhesus monkeys.

Hepatocellular carcinoma is the most common type of liver cancer in adults.

Approvals and indications of this drug were based on 3 main clinical trials.

Some pharmacy schools now use Pharmacy Curriculum Outcomes Assessment scores for academic probation.

Newly revised standards support quality education, and training for the technician workforce, according to the organizations.

Officials with the FDA are requiring safety label updates for fluoroquinolone antibiotics due to risks of mental health adverse effects, and blood sugar disturbances.

Even as fewer patients are using them, the 10 medications with the highest spend in Medicare Part D have seen substantial increases in spending and out-of-pocket costs.

Officials with the FDA are requiring safety label updates for fluoroquinolone antibiotics due to risks of mental health adverse effects and blood sugar disturbances, according to a press release